your health, our priority

A comprehensive tumor and blood genomic profiling is a cancer test for cancer therapy selection across all types of solid tumors and blood cancers. It supports immune therapy and targeted therapy selection, hereditary cancer risk assessment, and personalized cancer tracking to guide precise and effective treatment decisions. 

This integrates cutting- edge genomic and transcriptomic profiling with AI-enhanced ctDNA-MRD monitoring, empowering clinicians to deliver personalized cancer care. Our platform aligns with guidelines from leading organizations, including: the National Comprehensive Cancer Network (NCCN), European Society for Medical Oncology (ESMO), and the   U.S. Food and   Drug Administration (FDA).

By integrating DNA, RNA, and ctDNA insights delivers:

• Comprehensive biomarker coverage for diagnosis, prognosis, and therapy selection.
• Enhanced detection of rare structural variants and fusion events.
• Boosts detection sensitivity by 25% for both common and rare fusion variants.
• Utilizes a machine-learning model to predict tumor origin in Cancer of Unknown (CUP), enabling site-specific therapy.

This approach provides a comprehensive molecular landscape of  tumor, facilitating informed clinical improving patient outcomes.